Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC (Review)
- Authors:
- Lige Qiu
- Hailiang Li
- Sirui Fu
- Xiaofang Chen
- Ligong Lu
-
Affiliations: Department of Intervention, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, Guangdong 519000, P.R. China - Published online on: December 8, 2017 https://doi.org/10.3892/ol.2017.7568
- Pages: 2039-2048
This article is mentioned in:
Abstract
 |
|
Fan ST, Lo Mau C, Poon RT, Yeung C, Liu Leung C, Yuen WK, Ming LC, Ng KK and Chan Ching S: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: A 20-year experience. Ann Surg. 253:745–758. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J and Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Woerns MA and Galle PR: Future perspectives in hepatocellular carcinoma. Digest Liver Dis. 42 Suppl 3:S302–S309. 2010. View Article : Google Scholar | |
|
Rountree CB, Mishra L and Willenbring H: Stem cells in liver diseases and cancer: Recent advances on the path to new therapies. Hepatology. 55:298–306. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ji J and Wang XW: Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol. 39:461–472. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A and Vallera DA: Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 130:579–587. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Liu Q, Xiao J and Du J: EpCAM-antibody-labeled noncytotoxic polymer vesicles for cancer stem cells-targeted delivery of anticancer drug and siRNA. Biomacromolecules. 16:1695–1705. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, Zhou A, Eyob H, Balakrishnan S, Wang CY, et al: Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526:131–135. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Fan Y, Qi Y, Liu D, Wu K, Wen F and Zhao S: Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin. Oncol Rep. 34:929–935. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Iacopino F, Angelucci C, Piacentini R, Biamonte F, Mangiola A, Maira G, Grassi C and Sica G: Isolation of cancer stem cells from three human glioblastoma cell lines: Characterization of two selected clones. Plos One. 9:e1051662014. View Article : Google Scholar : PubMed/NCBI | |
|
Steiner JW, Perz ZM and Taichman LB: Cell population dynamics in the liver. A review of quantitative morphological techniques applied to the study of physiological and pathological growth. Exp Mol Pathol. 5:146–181. 1966. View Article : Google Scholar : PubMed/NCBI | |
|
Turner R, Lozoya O, Wang Y, Cardinale V, Gaudio E, Alpini G, Mendel G, Wauthier E, Barbier C, Alvaro D and Reid LM: Human hepatic stem cell and maturational liver lineage biology. Hepatology. 53:1035–1045. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Foster M, Al-Dhalimy M, Lagasse E, Finegold M and Grompe M: The origin and liver repopulating capacity of murine oval cells. Proc Natl Acad Sci USA. 100 Suppl 1:S11881–S11888. 2003. View Article : Google Scholar | |
|
Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R and Roskams T: Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol. 25:1388–1396. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Crosby HA, Hubscher SG, Joplin RE, Kelly DA and Strain AJ: Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology. 28:980–985. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, et al: Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res. 68:4287–4295. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Wang C, Lin Y, Liu Q, Yu LX, Tang L, Yan HX, Fu J, Chen Y, Zhang HL, et al: OV6+ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol. 57:613–620. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Navarro-Alvarez N, Soto-Gutierrez A and Kobayashi N: Hepatic stem cells and liver development. Methods Mol Biol. 640:181–236. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H and Taniguchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 44:240–251. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liu LL, Fu D, Ma Y and Shen XZ: The power and the promise of liver cancer stem cell markers. Stem Cells Dev. 20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gournay J, Auvigne I, Pichard V, Ligeza C, Bralet MP and Ferry N: In vivo cell lineage analysis during chemical hepatocarcinogenesis in rats using retroviral-mediated gene transfer: Evidence for dedifferentiation of mature hepatocytes. Lab Invest. 82:781–788. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sell S: Heterogeneity and plasticity of hepatocyte lineage cells. Hepatology. 33:738–750. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Dumble ML, Croager EJ, Yeoh GC and Quail EA: Generation and characterization of p53 null transformed hepatic progenitor cells: Oval cells give rise to hepatocellular carcinoma. Carcinogenesis. 23:435–445. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Shafritz DA, Oertel M, Menthena A, Nierhoff D and Dabeva MD: Liver stem cells and prospects for liver reconstitution by transplanted cells. Hepatology. 43:S89–S98. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Z and Mishra L: Cancer stem cells and hepatocellular carcinoma. Cancer Biol Ther. 8:1691–1698. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V and Roskams T: The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 49:138–151. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS and Lee WC: CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 9:3242009. View Article : Google Scholar : PubMed/NCBI | |
|
Okumoto K, Saito T, Haga H, Hattori E, Ishii R, Karasawa T, Suzuki A, Misawa K, Sanjo M, Ito JI, et al: Characteristics of rat bone marrow cells differentiated into a liver cell lineage and dynamics of the transplanted cells in the injured liver. J Gastroenterol. 41:62–69. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF and Mori M: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 24:506–513. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Maugeri-Saccà M, Vigneri P and De Maria R: Cancer stem cells and chemosensitivity. Clin Cancer Res. 17:4942–4947. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao M, Zheng S and Gu J: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 29:2289–2297. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and Li J: Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 126:2067–2078. 2010.PubMed/NCBI | |
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 27:1749–1758. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D and Yoon SK: CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315:129–137. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, et al: Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 62:1777–1786. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H, Nagano H, et al: CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 120:3326–3339. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Luo N, Luo Y, Peng Z, Zhang T and Li S: MicroRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol. 40:747–756. 2012.PubMed/NCBI | |
|
Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC and Wong J: Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: A prospective study. Ann Surg. 254:569–576. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 27:5660–5669. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Park CY, Tseng D and Weissman IL: Cancer stem cell-directed therapies: Recent data from the laboratory and clinic. Mol Ther. 17:219–230. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al: Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology. 57:1484–1497. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ and Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT and Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 13:153–166. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, et al: CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 72:3414–3423. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson GS, Hu Z, Duan W, Tian A, Wang XM, McLeod D, Lam V, George J and Qiao L: Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells. Stem Cells Dev. 22:2655–2664. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI | |
|
Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T and Moriwaki H: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 351:820–824. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, Ouafik L and Figarella-Branger D: A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol. 20:211–221. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK and Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization and molecular cloning. Blood. 90:5013–5021. 1997.PubMed/NCBI | |
|
Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X and Rafii S: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 103:2055–2061. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cioffi M, D'Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, Ieranó C, Cecere SC, Losito NS, Greggi S, et al: Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep. 5:103572015. View Article : Google Scholar : PubMed/NCBI | |
|
Swaminathan SK, Roger E, Toti U, Niu L, Ohlfest JR and Panyam J: CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release. 171:280–287. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rountree CB, Ding W, He L and Stiles B: Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells. 27:290–299. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T and Hayashi N: Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol. 52:872–879. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yao J, Zhang T, Ren J, Yu M and Wu G: Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep. 22:781–787. 2009.PubMed/NCBI | |
|
Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F and Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 62:1212–1218. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Salnikov AV, Kusumawidjaja G, Rausch V, Bruns H, Gross W, Khamidjanov A, Ryschich E, Gebhard MM, Moldenhauer G, Büchler MW, et al: Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 275:185–193. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Chen JN, Zeng TT, He F, Chen SP, Ma S, Bi J, Zhu XF and Guan XY: CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy. BMC Cancer. 16:152016. View Article : Google Scholar : PubMed/NCBI | |
|
Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schuler J, Wider D, et al: Effective eradication of glioblastoma stem cells by local application of an AC133/CD133-specific T-cell-engaging antibody and CD8 T cells. Cancer Res. 75:2166–2176. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, et al: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer. 99:100–109. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lang J, Lan X, Liu Y, Jin X, Wu T, Sun X, Wen Q and An R: Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts. Nucl Med Biol. 42:505–512. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun J, Zhang C, Liu G, Liu H, Zhou C, Lu Y, Zhou C, Yuan L and Li X: A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro. Clin Exp Metastasis. 29:185–196. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J and Zhang Q: Targeting glioblastoma cancer stem cell marker CD133 by heptapeptide-modified DSPE-PEG micelles. J Chin Pharm Sci. 24:2015. View Article : Google Scholar | |
|
Ashmun RA and Look AT: Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood. 75:462–469. 1990.PubMed/NCBI | |
|
Look AT, Ashmun RA, Shapiro LH and Peiper SC: Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest. 83:1299–1307. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Bralet MP, Pichard V and Ferry N: Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology. 36:623–630. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Guzman-Rojas L, Rangel R, Salameh A, Edwards JK, Dondossola E, Kim YG, Saghatelian A, Giordano RJ, Kolonin MG, Staquicini FI, et al: Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci USA. 109:1637–1642. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G and Kerbel RS: Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66:3386–3391. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Christ B, Stock P and Dollinger MM: CD13: Waving the flag for a novel cancer stem cell target. Hepatology. 53:1388–1390. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Reif AE and Allen JM: The AKR thymic antigen and its distribution in leukemias and nervous tissues. J Exp Med. 120:413–433. 1964. View Article : Google Scholar : PubMed/NCBI | |
|
Schlesinger M and Yron I: Antigenic changes in lymph-node cells after administration of antiserum to thymus cells. Science. 164:1412–1413. 1969. View Article : Google Scholar : PubMed/NCBI | |
|
Ades EW, Zwerner RK, Acton RT and Balch CM: Isolation and partial characterization of the human homologue of Thy-1. J Exp Med. 151:400–406. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ and Hu RM: Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 113:833–838. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT and Fan ST: Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 47:919–928. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY, Wang CY, Weng TY, Lai PT, Chen CS, et al: Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 6:42923–42937. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Noto Z, Yoshida T, Okabe M, Koike C, Fathy M, Tsuno H, Tomihara K, Arai N, Noguchi M and Nikaido T: CD44 and SSEA-4 positive cells in an oral cancer cell line HSC-4 possess cancer stem-like cell characteristics. Oral Oncol. 49:787–795. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pesarrodona M, Ferrer-Miralles N, Unzueta U, Gener P, Tatkiewicz W, Abasolo I, Ratera I, Veciana J, Schwartz S Jr, Villaverde A and Vazquez E: Intracellular targeting of CD44+ cells with self-assembling, protein only nanoparticles. Int J Pharm. 473:286–295. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, et al: Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 101:2145–2155. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S and Kipps TJ: Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci USA. 110:6127–6132. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cho JH, Lee SC, Ha NR, Lee SJ and Yoon MY: A novel peptide-based recognition probe for the sensitive detection of CD44 on breast cancer stem cells. Mol Cell Probes. 29:492–499. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Park HY, Lee KJ, Lee SJ and Yoon MY: Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. Mol Biotechnol. 51:212–220. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Munz M, Baeuerle PA and Gires O: The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 69:5627–5629. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schmelzer E and Reid LM: EpCAM expression in normal, non-pathological tissues. Front Biosci. 13:3096–3100. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Terris B, Cavard C and Perret C: EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 52:280–281. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cioffi M, Dorado J, Baeuerle PA and Heeschen C: EpCAM/CD3-bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 18:465–474. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Alibolandi M, Ramezani M, Sadeghi F, Abnous K and Hadizadeh F: Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm. 479:241–251. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gires O and Bauerle PA: EpCAM as a target in cancer therapy. J Clin Oncol. 28:e239–e242. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kurtz JE and Dufour P: Adecatumumab: An anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 10:951–958. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bae JS, Noh SJ, Jang KY, Park HS, Chung MJ, Park CK and Moon WS: Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Int J Oncol. 41:2150–2158. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tanimizu N, Nishikawa M, Saito H, Tsujimura T and Miyajima A: Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci. 116:1775–1786. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sununliganon L and Singhatanadgit W: Highly osteogenic PDL stem cell clones specifically express elevated levels of ICAM1, ITGB1 and TERT. Cytotechnology. 64:53–63. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Assis AC, Carvalho JL, Jacoby BA, Ferreira RL, Castanheira P, Diniz SO, Cardoso VN, Goes AM and Ferreira AJ: Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant. 19:219–230. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
De Francesco F, Tirino V, Desiderio V, Ferraro G, D'Andrea F, Giuliano M, Libondi G, Pirozzi G, De Rosa A and Papaccio G: Human CD34/CD90 ASCs are capable of growing as sphere clusters, producing high levels of VEGF and forming capillaries. PLoS One. 4:e65372009. View Article : Google Scholar : PubMed/NCBI | |
|
Brooke G, Tong H, Levesque JP and Atkinson K: Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev. 17:929–940. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J, Wang J, Zhang D, Cheng S and Liu S: Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. Gastroenterology. 144:1031–1041. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Barclay AN and Brown MH: The SIRP family of receptors and immune regulation. Nat Rev Immunol. 6:457–464. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Oldenborg PA, Gresham HD and Lindberg FP: CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 193:855–862. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y, Oldenborg PA, Ishikawa O and Matozaki T: Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 174:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg PA, Iizuka K, Yokoyama WM and Taylor PA: CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med. 194:541–549. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker of self on red blood cells. Science. 288:2051–2054. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138:286–299. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, et al: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2:63ra942010. View Article : Google Scholar : PubMed/NCBI | |
|
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J and Ng IO: Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 60:179–191. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lei ZJ, Wang J, Xiao HL, Guo Y, Wang T, Li Q, Liu L, Luo X, Fan LL, Lin L, et al: Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signaling. Oncogene. 34:32142015. View Article : Google Scholar : PubMed/NCBI |
